Prognostic Value of Serum S-100B in Malignant Melanoma

Moore B.W. : A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun, 19: 739–744, 1965.

Donato R. : Perspectives in S-100 protein biology. Cell Calcium, 12: 713–726, 1991.

Nakajima T. , Watanabe S. , Sato Y. , Kameya T. , Hirota T. , Shimosato Y. : An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol, 6: 715–727, 1982.

Huang C.L. , Provost N. , Marghoob A.A. , Kopf A.W. , Levin L. , Bart R.S. : Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol, 39: 451–463, 1998.

Guo H.B. , Stoffel-Wagner B. , Bierwirth T. , Mezger J. , Kling-muller D. : Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer, 31: 924–928, 1995.

Henze G. , Dummer R. , Joller-Jemelka H.I. , Boni R. , Burg G. : Serum S100: a marker for disease monitoring in metastatic melanoma. Dermatology, 194: 208–212, 1997.

Schultz E.S. , Diepgen T.L. , von den Driesch P. : Clinical and prognostic relevance of serum S100B protein in malignant melanoma. Br J Dermatol, 138: 426–430, 1998.

Kaskel P. , Berking C. , Sander S. , Volkenandt M. , Peter R.U. , Krähn G. : S100 protein in peripheral blood: a marker for melanoma metastases. J Am Acad Dermatol, 41: 962–969, 1999.

Bonfrer J.M. , Korse C.M. , Nieweg O.E. , Rankin E.M. : The luminescence immunoassay S100: a sensitive test to measure circulating S100b: its prognostic value in malignant melanoma. Br J Cancer, 77: 2210–2214, 1998.

Abraha H. , Fuller L. , du Vivier A. , Higgins E. , Sherwood R. : Serum S100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol, 137: 381–385, 1997.

Schmitz C. , Brenner W. , Henze E. , Christophers E. , Hauschild A. : Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res, 20: 5059–5063, 2000.

Jury C.S. , McAllister E.J. , MacKie R.M. : Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol, 143: 269–274, 2000.

Hauschild A. , Michaelsen J. , Brenner W. , Rudolph P. , Glaser R. , Henze E. , Christophers E. : Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res, 9: 155–161, 1999.

Curry B.J. , Farrelly M. , Hersey P. : Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma: Melanoma Res, 9: 557–567, 1999.

Djureen Mårtenson E. , Hansson L.O. , Nilsson B. , von Schoultz E. , Månsson Brahme E. , Ringborg U. , Hansson J. : Serum S100B protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncology, 19: 824–831, 2001.

Deichmann M. , Benner A. , Bock M. , Jackel A. , Uhl K. , Waldmann V. , Naher H. : S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol, 17: 1891–1896, 1999.

Mohammed M.Q. , Abraha H.D. , Sherwood R.A. , MacRae K. , Retsas S. : Serum S100beta protein as a marker of disease activity in patients with malignant melanoma. Med Oncol, 18: 109–120, 2001.

Krahn G. , Kaskel P. , Sander S. , Waizenhofer P.J. , Wortmann S. , Leiter U. , Peter R.U. : S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res, 21: 1311–1316, 2001.

Lesimple T. , Quillien V. , Brouard M. : The usefulness of serum S100B in the follow up of malignant melanoma. In: Third International Conference on the Adjuvant Therapy of Malignant Melanoma, London, March 19-20, Royal College of Physicians, London, UK, 1999 (abstract).

Mackie R.M. , McAllister E.J. : Rising levels of serum S100 protein precede other evidence of recurrence in patients with AJCC stage 3b malignant melanoma. In: Third International Conference on the Adjuvant Therapy of Malignant Melanoma, London, March 19-20, Royal College of Physicians, London, UK, 1999 (abstract).

Hauschild A. , Engel G. , Brenner W. , Glaser R. , Monig H. , Henze E. , Christophers E. : Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 140: 1065–1071, 1999.

Juergensen A. , Holzapfel U. , Hein R. , Stolz W. , Buettner R. , Bosserhoff A. : Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumour Biol 22: 54–58, 2001.

Acland K. , Evans A.V. , Abraha H. , Healy C.M. , Roblin P. , Calonje E. , Orchard G. , Higgins E. , Sherwood R. , Russell-Jones R. : Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol, 146: 832–835, 2002.

Bosserhoff A.K. , Kaufmann M. , Kaluza B. , Bartke I. , Zirngibl H. , Hein R. , Stolz W. , Buettner R. : Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res, 57: 3149–3153, 1997.

Seregni E. , Massaron S. , Martinetti A. , Illeni M.T. , Rovini D. , Belli F. , Agresti R. , Greco M. , Cascinelli N. , Bombardieri E. : S100 protein serum levels in cutaneous malignant melanoma. Oncol Rep, 5: 601–604, 1998.